KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$83.3 million.

  • Pacira BioSciences' Cash from Investing Activities rose 183.61% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.8 million, marking a year-over-year increase of 207.04%. This contributed to the annual value of -$83.3 million for FY2024, which is 207.40% down from last year.
  • Per Pacira BioSciences' latest filing, its Cash from Investing Activities stood at -$83.3 million for FY2024, which was down 207.40% from $77.5 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Cash from Investing Activities registered a high of $77.5 million during FY2023, and its lowest value of -$277.6 million during FY2020.
  • For the 3-year period, Pacira BioSciences' Cash from Investing Activities averaged around -$77.0 million, with its median value being -$83.3 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 983.14% in 2022, then surged by 134.43% in 2023.
  • Pacira BioSciences' Cash from Investing Activities (Yearly) stood at -$277.6 million in 2020, then soared by 92.51% to -$20.8 million in 2021, then crashed by 983.14% to -$225.2 million in 2022, then spiked by 134.43% to $77.5 million in 2023, then crashed by 207.40% to -$83.3 million in 2024.